LifeTech ScientificLFTSF 96 PS Ratio is 5.31 as of Jul. 03, 2026, which is 51% below its 10-year median of 10.77. GuruFocus rates LFTSF with a GF Score™ of 96/100 and a GF Value™ of $0.33. The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, LifeTech Scientific ranks worse than 65.22% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, LifeTech Scientific's share price is $0.2335.
LifeTech Scientific's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.04. Hence, LifeTech Scientific's PS Ratio for today is 5.31.
Good Sign:
LifeTech Scientific Corp stock PS Ratio (=4.31) is close to 10-year low of 3.99.
The historical rank and industry rank for LifeTech Scientific's PS Ratio or its related term are showing as below:
LFTSF'
s PS Ratio Range Over the Past 10 Years
Min: 3.99 Med: 10.77 Max: 31.68
Current: 4.34
During the past 13 years, LifeTech Scientific's highest PS Ratio was 31.68. The lowest was 3.99. And the median was 10.77.
LFTSF's PS Ratio is ranked worse than 65.22% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs LFTSF: 4.34
During the past 12 months, the average Revenue per Share Growth Rate of LifeTech Scientific was 8.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 7.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 13.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 15.50% per year.
During the past 13 years, LifeTech Scientific's highest 3-Year average Revenue per Share Growth Rate was 22.10% per year. The lowest was 5.00% per year. And the median was 15.60% per year.
Back to Basics: PS Ratio
LifeTech Scientific (OTCPK:LFTSF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
LifeTech Scientific PS Ratio Related Terms
LifeTech Scientific PS Ratio Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LifeTech Scientific's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's PS Ratio distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
LifeTech Scientific's Share Price of today is $0.2335.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LifeTech Scientific's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
LifeTech Scientific (LFTSF) has a PS Ratio of 5.31 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on LifeTech Scientific and its competitors. This is 51% below median its historical median of 10.77. Over the past decade, LifeTech Scientific's PS Ratio has ranged from 3.99 to 31.68. According to the industry distribution chart, LifeTech Scientific ranks #525 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 65.2%.
Is LifeTech Scientific's PS Ratio too high?
LifeTech Scientific's current PS Ratio of 5.31 is 51% below median its 10-year median of 10.77. Over the past 10 years, this metric has ranged from a low of 3.99 to a high of 31.68. The Medical Devices & Instruments industry median PS Ratio is 2.94. LifeTech Scientific's value of 5.31 is 80.6% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #525 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LifeTech Scientific has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #525 out of 805 companies for PS Ratio. This places LifeTech Scientific in the lower half of its industry. The industry median PS Ratio is 2.94. LifeTech Scientific's value of 5.31 is 80.6% above this benchmark. Historically, LifeTech Scientific's own PS Ratio has ranged from 3.99 to 31.68 over the past decade. While the company's 10-year median is 10.77 vs. the industry median of 2.94, LifeTech Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current PS Ratio of 5.31 is 80.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on LifeTech Scientific and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current PS Ratio is 5.31, which is 51% below median its own 10-year median of 10.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (LFTSF) has a current PS Ratio of 5.31. The stock's GF Value™ is $0.33, compared to a current price of $0.23 — trading 29.2% below its estimated fair value. The current PS Ratio is 5.31, which is 51% below median its 10-year median of 10.77 and 80.6% above the Medical Devices & Instruments industry median of 2.94. LifeTech Scientific's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For LifeTech Scientific (LFTSF), the current PS Ratio is 5.31 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (LFTSF) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of $0.23 is trading 29.2% below its estimated GF Value™ of $0.33.
Key valuation signals for LFTSF:
PS Ratio: 5.31 (51% below median its 10-year median of 10.77)
GF Value™: $0.33 vs. price of $0.23 (29.2% below fair value)
Industry Position: 80.6% above the Medical Devices & Instruments median (#525 of 805)
No single metric tells the full story. See the LFTSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
96GF Score
Get the complete analysis for LFTSF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFTSF has been successfully added to your 
